Tenax Therapeutics (NASDAQ:TENX) Now Covered by Analysts at StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of Tenax Therapeutics (NASDAQ:TENXGet Rating) in a research report issued on Monday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

Tenax Therapeutics Stock Performance

TENX opened at $0.14 on Monday. The firm has a 50-day moving average of $0.16 and a 200 day moving average of $0.32. Tenax Therapeutics has a fifty-two week low of $0.08 and a fifty-two week high of $1.46.

Hedge Funds Weigh In On Tenax Therapeutics

An institutional investor recently raised its position in Tenax Therapeutics stock. Armistice Capital LLC increased its position in Tenax Therapeutics, Inc. (NASDAQ:TENXGet Rating) by 23.1% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,965,885 shares of the specialty pharmaceutical company’s stock after acquiring an additional 368,836 shares during the quarter. Armistice Capital LLC owned about 7.80% of Tenax Therapeutics worth $334,000 at the end of the most recent quarter. 41.94% of the stock is currently owned by hedge funds and other institutional investors.

Tenax Therapeutics Company Profile

(Get Rating)

Tenax Therapeutics, Inc, a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension.

Featured Stories

Receive News & Ratings for Tenax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.